HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Heparin Surface-Modified Poly(methylmethacrylate) and Foldable Hydrophobic Acrylic Intraocular Lenses in Cataract Patients with Acquired Immune Deficiency Syndrome and CMV-Retinitis].

AbstractBACKGROUND:
In HIV-positive patients with necrotising retinitis, well-tolerated lens material as well as minimal invasive surgery to avoid postoperative complications are imperative. Heparin surface-modified PMMA-IOLs as well as acrylic IOLs are associated with less postoperative inflammation than conventional intraocular lenses.
METHODS:
In this randomised prospective clinical trial 18 patients received 7 HSM-IOLs through a self-sealing scleral tunnel and 11 foldable Acrysof-IOLs through a self-sealing limbal tunnel incision by the same surgeon. 7 of the 18 eyes were silicone oil-filled before cataract surgery, one eye received oil after the IOL implantation. Visual acuity, intraocular pressure, contrast sensitivity, intraocular inflammation and posterior capsule opacification were assessed. The follow-up period was 1 year.
RESULTS:
Eyes with Acrysof-IOLs were associated with lower, but not statistically significant, laser flare photometry values (photon counts/ms) than those with HSM-IOLs pre- (90.18 +/- 54.7 vs. 73.92 +/- 6.44) and 3 months post-surgery (69.06 +/- 8.27 vs. 55.03 +/- 7.75). 6 of the 7 eyes with HSM-IOL and 3 eyes of the Acrysof-group developed a dense posterior capsule opacification (PCO), 2 eyes had no and 6 eyes only a distinct PCO. YAG capsulotomy did not improve visual acuity in any case but retinal examination was again possible. Eyes with Acryl-IOL showed pre- and postoperatively a better visual acuity than eyes with HSM-IOL ("hand movement" - 0.4 vs. "no light perception" - 0.1 pre- and 0.05 - 0.6 vs. "no light perception" - 0.1 3 months postoperatively. Contrast sensitivity testing (Vistech method) could be performed in the PMMA-group preoperatively only in 1 eye (A1), in the Acryl-group in 2 eyes (A4, B4, C2, D2) and revealed postoperatively "no contrast vision" - A1, B2, C1 vs. "no contrast vision" - A2, B2, C3, D1, E1. The intraocular pressure was preoperatively 13.86 mm Hg (PMMA) vs. 14.82 mm Hg (Acrysof) and 14.4 mm Hg vs. 12.89 mm Hg 3 months post surgery.
CONCLUSION:
In the parameters we observed there was no statistical significant difference between heparin-surface modified (Pharmacia 811 C) and hydrophobic acrylic IOLs (Alcon Acrysof MA60BM) in patients with AIDS. As foldable Acrysof-IOLs can be implanted through a self-sealing bloodless tunnel incision and are associated with less posterior capsule opacification we prefer this IOL type in cataract surgery of AIDS patients.
AuthorsSusanne Krieglsteiner, Herrmann O C Gümbel, Thomas Kohnen
JournalKlinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 221 Issue 1 Pg. 40-6 (Jan 2004) ISSN: 0023-2165 [Print] Germany
Vernacular TitleHeparinbeschichtete Polymethylmethacrylat- und faltbare hydrophobe Acrylatintraokularlinsen bei Kataraktpatienten mit erworbenem Immundefektsyndrom und CMV-Retinitis.
PMID14745677 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Acrylates
  • Coated Materials, Biocompatible
  • Silicone Oils
  • Polymethyl Methacrylate
Topics
  • AIDS-Related Opportunistic Infections (complications)
  • Acquired Immunodeficiency Syndrome (complications)
  • Acrylates
  • Adult
  • Coated Materials, Biocompatible
  • Cytomegalovirus Retinitis (complications)
  • Equipment Failure Analysis
  • Female
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Keratitis, Herpetic (surgery)
  • Male
  • Middle Aged
  • Polymethyl Methacrylate
  • Postoperative Complications (etiology, prevention & control)
  • Prosthesis Design
  • Reoperation
  • Retinal Detachment (surgery)
  • Retinal Necrosis Syndrome, Acute (complications)
  • Risk Factors
  • Silicone Oils (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: